Rodman & Renshaw Initiates Coverage On Karyopharm Therapeutics with Buy Rating, Announces Price Target of $28

Karyopharm Therapeutics, Inc. +12.55% Pre

Karyopharm Therapeutics, Inc.

KPTI

8.16

8.16

+12.55%

0.00% Pre
Rodman & Renshaw analyst Michael King initiates coverage on Karyopharm Therapeutics (NASDAQ: KPTI) with a Buy rating and announces Price Target of $28.